Abstract P3-11-01: Treatment patterns for young women with HR+/HER2- metastatic breast cancer in the United States in the era of CDK 4/6 inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs17-p3-11-01
Abstract: Background : NCCN guidelines recommend that premenopausal women with HR+/HER2- metastatic breast cancer (MBC) be rendered postmenopausal and then treated accordingly. After its approval in February 2015, the CDK4/6 inhibitor palbociclib (P), in combination with… read more here.
Keywords: her2 mbc; treatment; breast cancer; women her2 ... See more keywords
Oncofertility counselling in premenopausal women with HER2-positive breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Oncotarget"
DOI: 10.18632/oncotarget.26565
Abstract: A complete oncofertility counselling should be offered to all premenopausal patients before the administration of anticancer treatments. This important discussion is a crucial step for allowing them to take fully informed decisions about the proposed… read more here.
Keywords: premenopausal women; her2 positive; induced amenorrhea; treatment induced ... See more keywords